Business Context and Reporting Period
Company: Intelligent Bio Solutions Inc. (INBS)
Filing Type: Form 10-K (Annual Report)
Period Ended: June 30, 2026
Business Overview: INBS is a medical technology company focused on non-invasive testing solutions. Its primary commercial product is the Intelligent Fingerprinting (IFP) System, which uses fingerprint sweat to screen for drugs of abuse. The company operates globally with headquarters in New York and manufacturing in Cambridge, UK. In December 2025, the company effected a 1-for-10 reverse stock split to maintain Nasdaq listing compliance.
Key Financial Metrics
| Metric | Fiscal Year 2026 | Fiscal Year 2025 |
|---|---|---|
| Revenue | $4,215,175 | $3,052,532 |
| Gross Profit | $2,049,994 | $1,246,859 |
| Gross Margin | 48.6% | 40.9% |
| Net Loss (Attributable to INBS) | $(12,430,975) | $(10,568,733) |
| Cash and Cash Equivalents | $3,992,312 | $1,019,909 |
| Working Capital | $2,168,312 | $(212,419) |
| Operating Cash Flow | $(11,927,222) | $(9,677,313) |
Revenue Breakdown (2026): Cartridges ($2.49M), Readers ($0.90M), Accessories ($0.83M).
Government Support Income: $677,776 (primarily R&D tax refunds).
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 38.1% year-over-year, driven by a 41.1% increase in cartridge sales and the addition of 116 new customers.
- Margin Expansion: Gross margin improved from 40.9% to 48.6%, attributed to a strategic manufacturing partnership with Syrma Johari MedTech Ltd., operational efficiencies, and a favorable sales mix.
- Increased Operating Expenses: Total operating expenses rose to $15.3M from $12.7M. Selling, General, and Administrative (SG&A) expenses increased by $1.6M due to marketing and investor relations efforts. Development and regulatory expenses increased by $0.97M to support FDA 510(k) submissions.
- Liquidity Position: Cash balances increased significantly from $1.02M to $3.99M, bolstered by a $10.0M private placement in January 2026 and warrant exercises.
Guidance, Outlook, Risks, and Unusual Items
Outlook and Management Commentary
Management is focused on securing FDA 510(k) clearance for the IFP System to detect codeine, which is critical for U.S. market expansion. Recent clinical studies (Interference Study, Method Comparison Study) were initiated in 2026 to support this submission. The company aims to expand into the APAC region and new customer segments (law enforcement, airlines).
Risks and Contingencies
- Going Concern: The independent auditor has included an explanatory paragraph regarding substantial doubt about the company's ability to continue as a going concern. Management believes current cash ($3.99M) may be insufficient to fund operations for the next 12 months without additional financing.
- Regulatory Uncertainty: Delays or failure to obtain FDA clearance would materially harm the business. The company is currently navigating a resubmission process for its 510(k) application.
- Intellectual Property: Licensing for the Biosensor Platform (BPT) and COV2 products is on hold due to the liquidation of the licensor, Life Science Biosensor Diagnostics Pty Ltd (LSBD). IP rights have reverted to the University of Newcastle, and finalization of new terms is uncertain.
- Grant Repayment: The company owes $1.25M to the Australian Government regarding a manufacturing facility grant, payable in monthly installments.
Unusual Items
Impairment of Long-Lived Assets: The company recognized an impairment loss of $298,555 related to construction-in-progress assets held for sale in Australia.
Investor Verification Checklist
- Capital Adequacy: Verify the timeline and terms of the next anticipated capital raise, given the "substantial doubt" going concern warning.
- FDA Status: Confirm the current status of the FDA 510(k) resubmission for codeine detection and the expected timeline for clearance.
- Grant Liability: Review the repayment schedule for the $1.25M Australian Government grant obligation.
- IP Licensing: Monitor updates on the re-licensing negotiations with the University of Newcastle for the Biosensor Platform technology.
- Manufacturing Partnership: Assess the performance and cost-benefit realization of the new manufacturing partnership with Syrma Johari MedTech Ltd.